| CAS NO: | 138383-07-0 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 138383-07-0 |
| 别名 | SQ31765; SQ 31765 |
| Canonical SMILES | O=C1N(CCN(C)C)C2=CC=CC(C(F)(F)F)=C2C[C@@H](C3=CC=C(OC)C=C3)[C@H]1OC(C)=O |
| 分子式 | C24H27F3N2O4 |
| 分子量 | 464.48 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 半岛bd体育手机客户端 描述 | SQ-31765 is a benzazepine calcium channel blocker. SQ-31765 (SQ 31,765) can reduce the severity of ischemia in a manner which is independent of changes in myocardial blood flow or hemodynamic alterations. Anesthetized dogs are given saline (n=6), SQ-31765 (n=6; 0.2 mg/kg) or SQ 32,189 (n=6; 0.2 mg/kg) i.v. 10 min before ischemia. The effect on pacing-induced ST-segment elevation (pacing+left anterior descending coronary artery stenosis) and myocardial blood flow are determined. SQ-31765 reduces ST-elevation (P<0.05) compared to saline at 10, 40 and 70 min after infusion (5.9±1.4 and 12.0±1.4 mV, respectively, at 70 min). Left anterior descending coronary artery stenosis during atrial pacing resulted in a significant reduction in subendocardial flow in all groups before drug infusion (41±7, 44±7 and 35±9 mL/min/100 g for saline, SQ-31765 and SQ 32,189, respectively)[1]. [1]. Grover GJ, et al. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765. J Pharmacol Exp Ther. 1989 Dec;251(3):1020-5. |
m.cnreagent.com